Cargando…
Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial—EPOC 2 (JFMC49-1601-C5)
BACKGROUND: Oral mucositis (OM) is an unpleasant adverse event in patients receiving chemotherapy. A prospective feasibility study showed that elemental diet (ED), an oral supplement that does not require digestion, may prevent OM. Based on this, we established a central review system for oral cavit...
Autores principales: | Tanaka, Y., Takeuchi, H., Nakashima, Y., Nagano, H., Ueno, T., Tomizuka, K., Morita, S., Emi, Y., Hamai, Y., Hihara, J., Saeki, H., Oki, E., Kunisaki, C., Otsuji, E., Baba, H., Matsubara, H., Maehara, Y., Kitagawa, Y., Yoshida, K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511839/ https://www.ncbi.nlm.nih.gov/pubmed/34626918 http://dx.doi.org/10.1016/j.esmoop.2021.100277 |
Ejemplares similares
-
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)
por: Oki, E., et al.
Publicado: (2016) -
A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.
por: Ando, M., et al.
Publicado: (1998) -
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
por: Takahashi, T., et al.
Publicado: (2021) -
Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
por: Katori, H, et al.
Publicado: (2004) -
Smart Pellets for Controlled Delivery of 5-Fluorouracil
por: Bayan, Mohammad F., et al.
Publicado: (2022)